The content on this site is intended for healthcare professionals only
Dr João Glasberg speaks to ecancer about METNET which is a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours. He initially talks about the background of the study.
The aim of the study was to evaluate the efficacy and safety of metformin monotherapy in patients with advanced/metastatic well-differentiated NET (WD-NET) of gastroenteropancreatic (GEP) or pulmonary origin.
Dr Glasberg then discusses the methodology and key results of the study. The study indicated that metformin monotherapy offers modest antitumour activity in well-differentiated GEP or lung NET.
Dr Glasberg concludes by discussing how these results can impact the future treatment of neuroendocrine tumours.
Read the study here.
DLL3 expression in circulating tumour cells predicts response to tarlatamab in small cell lung cancer
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Understanding the use of PARPi combinations to treat patients with mCRPC
